175 related articles for article (PubMed ID: 24615985)
1. Synthesis and antitumor activities of some new N1-(flavon-6-yl)amidrazone derivatives.
Habashneh AY; El-Abadelah MM; Zihlif MA; Imraish A; Taha MO
Arch Pharm (Weinheim); 2014 Jun; 347(6):415-22. PubMed ID: 24615985
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity assays of some new N1-(flavon-7-yl)amidrazone derivatives and related congeners.
Abu-Aisheh MN; Mustafa MS; El-Abadelah MM; Naffa RG; Ismail SI; Zihlif MA; Taha MO; Mubarak MS
Eur J Med Chem; 2012 Aug; 54():65-74. PubMed ID: 22677031
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors.
Pan X; Dong J; Gao H; Wang F; Zhang Y; Wang S; Zhang J
Chem Biol Drug Des; 2014 May; 83(5):592-9. PubMed ID: 24330598
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
Mojzych M; Šubertová V; Bielawska A; Bielawski K; Bazgier V; Berka K; Gucký T; Fornal E; Kryštof V
Eur J Med Chem; 2014 May; 78():217-24. PubMed ID: 24681986
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W
Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
10. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
[TBL] [Abstract][Full Text] [Related]
11. Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib.
Pan X; Dong J; Shao R; Su P; Shi Y; Wang J; He L
Bioorg Med Chem Lett; 2015 Oct; 25(19):4164-8. PubMed ID: 26298495
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and preclinical evaluation of NRC-AN-019.
Amala K; Bhujanga Rao AK; Gorantla B; Gondi CS; Rao JS
Int J Oncol; 2013 Jan; 42(1):168-78. PubMed ID: 23151973
[TBL] [Abstract][Full Text] [Related]
15. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
Ahmed MF; Belal A
Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
[TBL] [Abstract][Full Text] [Related]
17. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Ibrahim DA; Abou El Ella DA; El-Motwally AM; Aly RM
Eur J Med Chem; 2015 Sep; 102():115-31. PubMed ID: 26256032
[TBL] [Abstract][Full Text] [Related]
18. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
20. N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl.
Arioli F; Borrelli S; Colombo F; Falchi F; Filippi I; Crespan E; Naldini A; Scalia G; Silvani A; Maga G; Carraro F; Botta M; Passarella D
ChemMedChem; 2011 Nov; 6(11):2009-18. PubMed ID: 21990039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
